Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: Report of 22 cases

Liver International

Volumn 36, Issue 2, 2016, Pages 302-310

  Bessone, Fernando ^a   Lucena, Mi ^b,c   Roma, Marcelo G ^d   Stephens, Camilla ^b,c   Medina Cáliz, Inmaculada ^b,c   Frider, Bernardo ^e   Tsariktsian, Guillermo ^e   Hernández, Nelia ^f   Bruguera, Miquel ^g   Gualano, Gisela ^h   Fassio, Eduardo ^h   Montero, Joaquín ^a   Reggiardo, María V ^a   Ferretti, Sebastián ^a   Colombato, Luis ⁱ   Tanno, Federico ^a   Ferrer, Jaime ^a   Zeno, Lelio ^a   Tanno, Hugo ^a   Andrade, Raúl J ^b,c  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^e HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

^f DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^g HOSPITAL CLÍNIC   (Spain)

^h HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

ⁱ HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

Author keywords

Acute liver failure; Autoimmune hepatitis; Cyproterone acetate; Drug induced liver injury; Hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYPROTERONE ACETATE; PREDNISONE; TRANSFORMING GROWTH FACTOR; ANTIANDROGEN; ANTIINFLAMMATORY AGENT; CORTICOSTEROID;

ACUTE HEPATITIS; ADULT; ADVANCED CANCER; AGED; ALCOHOL CONSUMPTION; ARTICLE; ASCITES; AUTOIMMUNE HEPATITIS; CHOLESTATIC HEPATITIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; HEPATIC ENCEPHALOPATHY; HEPATITIS; HEPATORENAL SYNDROME; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; IRON OVERLOAD; JAUNDICE; LABORATORY TEST; LATENT PERIOD; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER HISTOLOGY; LIVER INJURY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PHENOTYPE; PHYSICAL EXAMINATION; PROSTATE CANCER; STEROID THERAPY; TOXIC HEPATITIS; TREATMENT DURATION; CHEMICAL AND DRUG INDUCED LIVER INJURY; LIVER; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTI-INFLAMMATORY AGENTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CYPROTERONE ACETATE; HUMANS; JAUNDICE; LIVER; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATIC NEOPLASMS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84955736522     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12899     Document Type: Article

References (46)

1. Baltogiannis D, Giannakopoulos X, Charalabopoulos K, etal. Monotherapy in advanced prostate cancer: an overview. Exp Oncol 2004; 26: 185-91.
2. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003; 91: 455-61.
3. Carmina E. A risk-benefit assessment of pharmacological therapies for hirsutism. Drug Saf 2001; 24: 267-76.
4. Lopez M, Natali M, Di Lauro L, etal. Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer 1993; 72: 502-5.
5. Wiegratz I, Kuhl H. Managing cutaneous manifestations of hyperandrogenic disorders: the role of oral contraceptives. Treat Endocrinol 2002; 1: 372-86.
6. Laron Z, Kauli R. Experience with cyproterone acetate in the treatment of precocious puberty. J Pediatr Endocrinol Metab 2000; 13(Suppl 1): 805-10.
7. Muneer A, Minhas S, Arya M, Ralph DJ. Stuttering priapism - a review of the therapeutic options. Int J Clin Pract 2008; 62: 1265-70.
8. Assumpção AA, Garcia FD, Garcia HD, Bradford JM, Thibaut F. Pharmacologic treatment of paraphilias. Psychiatr Clin North Am 2014; 37: 173-81.
9. Schroder FH. Cyproterone acetate - mechanism of action and clinical effectiveness in prostate cancer treatment. Cancer 1993; 72: 3810-5.
10. Barradell LB, Faulds D. Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer. Drugs Aging 1994; 5: 59-80.
11. 6-1, 2-methylen-17 a-hydroxyprogesteronacetat. Schilddrüsenhormone und Körperperipherie/Regulation der Schilddrüsenfunktion Symposion der Deutschen Gesellschaft für Endokrinologie Volume 10, 1964, Springer Berlin Heidelberg, pp 301-4.
12. Manso G, Thole Z, Salgueiro E, Revuelta P, Hidalgo A. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system. Pharmacoepidemiol Drug Saf 2006; 15: 253-9.
13. Chabbert-Buffet N, Amy JJ. The combination ethinylestradiol/cyproterone acetate is temporarily withdrawn from the market in France. Is the measure justified? Eur J Contracept Reprod Health Care 2013; 18: 75-8.
14. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343: d6423.
15. Levesque H, Trivalle C, Manchon ND, etal. Fulminant hepatitis due to cyproterone acetate. Lancet 1989; 1: 215-6.
16. Blake JC, Sawyerr AM, Dooley J, Scheuer PJ, McIntyre N. Severe hepatitis caused by cyproterone acetate. Gut 1990; 31: 556-7.
17. Drakos PE, Gez E, Catane R. Hepatitis due to cyproterone acetate. Eur J Cancer 1992; 28: 1931-2.
18. Roila F, Crino L, Carloni G, Natalini G. Cyproterone acetate: hepatotoxicity and prostatic cancer treatment. Ann Oncol 1993; 4: 701.
19. Murphy BJ, Collins BJ. Severe hepatitis and liver failure induced by cyproterone acetate. Aust N Z J Med 1996; 26: 724.
20. Bessone F, Passamonti ME, Ferrer J, etal. Severe hepatocellular damage-induced by cyproterone. Hepatology 1998; 28(Suppl): 1895A.
21. Meijers WH, Willemse PH, Sleijfer DT, Mulder NH, Grond J. Hepatocellular damage by cyproterone acetate. Eur J Cancer Clin Oncol 1986; 22: 1121-2.
22. Parys BT, Hamid S, Thomson RG. Severe hepatocellular dysfunction following cyproterone acetate therapy. Br J Urol 1991; 67: 312-3.
23. Castellani P, Bernardini D, Renou C, etal. Fatal sub-fulminant hepatitis caused by cyproterone acetate. A new case. Gastroenterol Clin Biol 1996; 20: 915-6.
24. Friedman G, Lamoureux E, Sherker AH. Fatal fulminant hepatic failure due to cyproterone acetate. Dig Dis Sci 1999; 44: 1362-3.
25. Hirsch D, Kovatz S, Bernheim J, Shenkman L. Fatal fulminant hepatitis from cyproterone acetate. Isr J Med Sci 1994; 30: 238-40.
26. Lombardi A, Ferrazza P, Castaldi F, etal. Acute hepatic necrosis in a patient treated with cyproterone acetate. G Chir 1998; 19: 161-3.
27. Bressollette L, Dubois A, Carlhant D, etal. Fatal hepatitis caused by cyproterone acetate. Therapie 1994; 49: 153.
28. Antoni M, Bourliere M, Toullec J, etal. Fatal subfulminant hepatitis caused by cyproterone acetate. Gastroenterol Clin Biol 1991; 15: 772-3.
29. Vodička M, Sálek T, Röderová E, Cerný D. Hepatotoxicity induced by cyproterone acetate in the prostate carcinoma treatment - a case report. Klin Onkol 2013; 26: 47-8.
30. Savidou I, Deutsch M, Soultati A, etal. Hepatotoxicity induced by cyproterone acetate: a report of three cases. World J Gastroenterol 2006; 12: 7551-5.
31. Abenavoli L, Milic N, Beaugrand M. Severe hepatitis induced by cyproterone acetate: role of corticosteroids. A case report. Ann Hepatol 2013; 12: 152-5.
32. Kim JH, Wook Yoo B, Yang WJ. Hepatic failure induced by cyproterone acetate: a case report and literature review. Can Urol Assoc J 2014; 8: e458-61.
33. Hennes EM, Zeniya M, Czaja AJ, etal. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76.
34. Aithal GP, Watkins PB, Andrade RJ, etal. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-15.
35. Benichou C, Danan G, Flahault A. Causality assessment ofadverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-6.
36. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 7: CD004425.
37. Falsetti L, Gambera A, Platto Q, Legrenzi L. Management of hirsutism. Am J Clin Dermatol 2000; 1: 89-99.
38. Thole Z, Manso G, Salgueiro E, Revuelta P, Hidalgo A. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol Int 2004; 73: 289-95.
39. Romero M, Palmer SL, Kahn JA, etal. Imaging appearance in acute liver failure: correlation with clinical and pathology findings. Dig Dis Sci 2014; 59: 1987-95.
40. Garty BZ, Dinari G, Gellvan A, Kauli R. Cirrhosis in a child with hypothalamic syndrome and central precocious puberty treated with cyproterone acetate. Eur J Pediatr 1999; 158: 367-70.
41. Kacar S, Akdogan M, Kosar Y, etal. Estrogen and cyproterone acetate combination-induced autoimmune hepatitis. J Clin Gastroenterol 2002; 35: 98-100.
42. Björnsson E, Talwalkar J, Treeprasertsuk S, etal. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51: 2040-8.
43. Lucena MI, Kaplowitz N, Hallal H, etal. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol 2011; 55: 820-7.
44. Moller S, Iversen P. Severe toxic hepatitis during flutamide (Eulexin) treatment. Ugeskr Laeger 1989; 151: 173-4.
45. Pontiroli L, Sartori M, Pittau S, etal. Flutamide-induced acute hepatitis: investigation on the role of immunoallergic mechanisms. Ital J Gastroenterol Hepatol 1998; 30: 310-4.
46. Fau D, Eugene D, Berson A, etal. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 1994; 269: 954-62.